Bristol Myers Squibb Company (NYSE:BMY) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,664,157 shares of the biopharmaceutical company's stock after purchasing an additional 97,997 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.08% of Bristol Myers Squibb worth $98,194,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BMY. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,989,525,000. Ameriprise Financial Inc. lifted its stake in shares of Bristol Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Bristol Myers Squibb by 701.2% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after purchasing an additional 10,913,708 shares during the last quarter. Wellington Management Group LLP raised its holdings in Bristol Myers Squibb by 3,880.0% in the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after buying an additional 5,827,317 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Bristol Myers Squibb in the fourth quarter valued at about $257,618,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president directly owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.07% of the company's stock.

Bristol Myers Squibb Stock Up 2.6%

Shares of NYSE:BMY traded up $1.20 during trading on Tuesday, hitting $47.49. 20,957,086 shares of the company were exchanged, compared to its average volume of 12,935,747. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The firm's 50 day moving average price is $47.85 and its 200-day moving average price is $53.84. The stock has a market capitalization of $96.65 billion, a P/E ratio of 17.79, a PEG ratio of 1.37 and a beta of 0.38. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the business earned ($4.40) EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.22%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BMY. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.